natgillin/translations-raw huggingface dataset:
Microparticles according to claim 1 wherein the cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] is an amourphous powder having a particle size less than about 5 microns. 
Mikročestice u skladu s bilo kojim prethodnim zahtjevom, naznačene time, da ciklo[(4Â«(NH>-C>Hu-NH-CO-O-)Proj-Phg-DTrp-Lys-Tyr(4-Bzl)Phe] je amorfni prašak koji ima veličinu čestica manju od oko 5 mikrona.
In parallel to said transistor 370 there is provided a capacitor 340, while the collector of transistor 370 is connected to the output 90u of operational amplifier 90 through a resistor 342. 
U paralelu spomenutog tranzistora 370 spojen je kondenzator 340, dok je kolektor tranzistora 370 spojen na izlaz 90u operacijskog pojačala 90, preko otpornika 342.
For microfluidic arrangements in general, the plate-shaped composite structure is preferably mechanically machined along lines which extend between the groove structures and which are not necessarily parting lines, so that thereafter the microfluidic arrangements in the composite structure are individually separated or are separated into groups but are not completely separated, or are in fact individually separated but are completely separated into groups. 
Za mikrofluidne naprave općenito, pločasta kompozitna struktura se ponajprije obrađuje strojno mehanički uzduž linija koje se protežu između brazdastih struktura i koje nisu nužno i razdjelne linije, tako da su nakon toga mikrofluidne naprave u kompozitnoj strukturi pojedinačno odvojene ili su odvojene u skupinama, ali nisu potpuno odvojene, ili su u stvari pojedinačno odvojene, ali nisu potpuno odvojene u skupinama.
a C1-8 alkoxy group which may be substituted by one or more R7A, 
(10) Cia alkoksi skupina, koja može biti supstituirana s jednom ili više hidroksi skupina;
iii) disinfecting and/or perfuming agents; 
iii) tvari za dezinfekciju i/ili parfimiranje;
The method of claim 14, wherein the Crenolanib or a salt thereof is provided as a single agent or in combination with another chemotherapeutic agent for treatment of pediatric patient with the proliferative disease. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 13, pri čemu se crenolanib ili njegova sol osigurava kao jedini agens ili u kombinaciji s drugim kemoterapijskim agensom za liječenje pedijatrijskog subjekta s akutnom mijeloičnom leukemijom (AML).
reacting a compound of formula with a compound of formula to form a compound having the formula: and 
reakcije spoja formule sa spojem formule da bi se formirao spoj koji ima formulu:
Normally, the radial blades extend helically about the longitudinal axis of the mixing member, and are angularly spaced about the axis so that the outer lateral edges of the blades lie on a cylindrical surface of a diameter approximately equal to but no larger than the diameter of the bowl; and one of the end hubs has a supporting shaft or pin projecting from the hub body, coaxially with the longitudinal axis of the mixing member, and terminating with a splined head for connection to an electric motor inside the blender. 
Normalno, radijalne lopatice se protežu spiralno oko uzdužne osi članka za miješanje i kutno su razmaknute oko ove osovine tako, da vanjski bočni bridovi lopatica leže na cilndričnoj plohi promjera koji je približno jednak, ali ne veći od promjcra zdjele; i jedna od krajnjih glavina ima potpornu osovinu ili štift koji strši iz tijela glavinc, koaksijalno s uzdužnom osovinom članka za miješanje i koji završava rebrastom glavom za povezivanje na električni motor unutar miješalice.
The combination for use according to any one of the preceding claims, wherein diabetes mellitus type 2 is not adequately controlled with metformin and insulin alone. 
Kombinacija namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što sami metformin i inzulin nisu dovoljna kontrola za dijabetes melitus tip 2.
A typical treatment regimen for IL-2 is to administer 18 x 106 IU per m2 per 24-hours as a continuous infusion for 5 days, followed by 2-6 days without receiving IL-2, then an additional 5 days of intravenous IL-2 as a continuous infusion as before, and then 3 weeks without receiving IL-2. 
Tipični režim liječenja za IL-2 jest da se daje 18310* TU po m" na 24 sata kao kontinuirana infuzija tijekom 5 dana, čemu slijedi 2-6 dana bez primanja IL-2, zatim dodatnih 5 dana intravenoznog IL-2 kao kontinuirane infuzije kao prije, a zatim 3 tjedna bez primanja IL-2.
The compound for use of claim 1, wherein the disease or disorder is genitourinary cancer. 
Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak jetre.
A monoclonal antibody or antigen-binding fragment thereof that binds human CGRP receptor, said human CGRP receptor comprising a human CRLR polypeptide and a human RAMP1 polypeptide, wherein the monoclonal antibody or antigen-binding fragment thereof binds to an epitope formed of amino acid residues from both CRLR and RAMP1 polypeptides, and wherein the monoclonal antibody or antigen-binding fragment thereof competes for binding to human CGRP receptor with a reference antibody, said reference antibody comprising (i) a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 161, 163, 164, 166, and 168; and (ii) a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 140, 143, 146, 148, and 150. 
Monoklonsko protutijelo ili njegov antigen-vezujući fragment koji veže ljudski CGRP receptor, navedeni ljudski CGRP receptor obuhvaća ljudski CRLR polipeptid i ljudski RAMPI polipeptid, naznačeno time što se monoklonsko protutijelo ili njegov antigen-vezujući fragment veže za epitop formiran od aminokiselinskih ostataka iz oba polipeptida CRLR i RAMPI, te pri čemu se monoklonsko protutijelo ili njegov antigen-vezujući fragment natječe za vezanje na ljudski CGRP receptor s referentnim protutijelom, pri čemu navedeno referentno protutijelo sadrži (i) varijabilnu regiju teškog lanca koja sadrži sekvencu odabranu iz skupine koja se sastoji od SEQ ID NOs: 161, 163, 164, 166, 1 168; i (11) varijabilnu regiju laganog lanca koja sadrži sekvencu odabranu iz skupine koja se sastoji od SEQ ID NOs: 140, 143, 146, 148, i 150.
The compound according to claim 1, wherein R4 and R5 taken together with the nitrogen atom to which they are attached form 1,3-dihydro-isoindolyl. 
R4 i Rs, uzeti zajedno s atomom dušika na kojeg su vezani, tvore 1,3-dihidroizoindolil.
A lighting module of claim 1, wherein said microchip is energized by a power source, wherein the energy of said power source depletes over time. 
Rasvjetni modul iz patentnog zahtjeva 1, naznačen time, da se navedeni mikročip napaja iz izvora energije pri čemu se navedeni izvor energije s vremenom troši.
The compound or a salt thereof according to claim 6, wherein R12 is halogen or halogeno-lower alkyl, and R1, R13 and R14 are H. 
Spoj ili njegova sol u skladu sa patentnim zahtjevom 6, gdje R12 je halogen ili halogeno-C1-6 alkil, i R11, R13 i R14 su H.
A compound according to claim 1, which is a trifluoroacetate salt, a sulfate salt or a hydrochloride salt. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je trifluoracetatna sol, sulfatna sol ili hidrokloridna sol.
In a preferred embodiment, the process for the manufacture of 2-[(3,5-difluoro-3′-methoxy-1,1′-biphenyl-4-yl)amino]nicotinic acid comprises the steps of: reacting 4-bromo-2,6-difluoroaniline with 3-methoxyphenylboronic acid to obtain 3,5-difluoro-3′-methoxybiphenyl-4-amine, forming and isolating an aminium salt of 3,5-difluoro-3′-methoxybiphenyl-4-amine obtained in step a) by mixing an acid selected from the group consisting of hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, p-toluenesulfonic acid and mixtures thereof with a solution or suspension of 3,5-difluoro-3′-methoxybiphenyl-4-amine in a solvent selected from the group consisting of n-hexane, dichloromethane, ethylene glycol, propylene glycol, n-propyl acetate, isopropyl acetate and mixtures thereof, 
Postupak prema zahtjevu 1 koji se sastoji od sljedećih koraka: a) reakcije 4-bromo-2,6-difluoroanilina s 3-metoksifenilbornom kiselinom kako bi se dobio 3,5-difluoro-3?- metoksibifenil-4-amin, b) formiranje i izdvajanje aminijeve soli 3,5-difluoro-3'-metoksibifenil-4-amina dobivenog u koraku a) miješanjem kiseline odabrane iz skupine koja se sastoji od klorovodične kiseline, dušične kiseline, fosforne kiseline, sumporne kiseline, p-toluensulfonske kiseline i njihovih smjesa s otopinom ili suspenzijom 3,5-difluoro-3'-metoksibifenil-4-amina u otapalu odabranom iz skupine koja se sastoji od n-heksana, diklorometana, etilen glikola, propilen glikola, n-propil acetata, izopropil acetata i njihovih smjesa, c1) reakcije aminijeve soli 3,5-difluoro-3'-metoksibifenil-4-amina iz koraka b) s 2-kloronikotinskom kiselinom.
a second portion having a smaller particle size, the second portion comprising zircon flour; and providing a colloidal silica binder at 5 wt % to 20 wt % of the dry weight of the first set of components, mixing the first set of components with the colloidal silica binder to form a refractory composition comprising 55 wt % to 65 wt % alumina, 20 wt % to 25 wt % zirconia, and 15 wt % to 25 wt % silica; and 
Metoda za pripremu vatrostalnog, obuhvaća: osiguravanje prvog seta komponenata koji obuhvaća aluminij i cirkon; osiguravanje koloidnog silicijevog veziva s 5 wt% do 20 wt% suhe težine prvog seta komponenata; miješanje prvog seta komponenata s koloidnim silicijevim vezivom za tvorbu vatrostalnog sastava obuhvaća 55 wt% do 65 wt% aluminija, 20 wt% do 25 wt% cirkona i 15 wt% do 25 wt% silicija; 1 stvaranje vatrostalnog sastava na površini ložišta.
A fusion peptide according to claim 13, wherein component (III) comprises at least four amino acid residues, preferably at least 10 additional amino acid residues, more preferably at least 20, or at least 30. 
Fuzijski peptid prema patentnom zahtjevu 9, naznačen time da komponenta (III) obuhvaća najmanje četiri aminokiselinska ostatka, ili poželjno obuhvaća najmanje 10 aminokiselinskih ostataka, ili još poželjnije obuhvaća najmanje 20 aminokiselinskih ostataka.
The remainder of the cells were swollen with 0.075 M KCl, washed with three consecutive changes of fixative (methanol:glacial acetic acid, 3:1 v/v), capped and stored overnight or longer at approximately 2-8°C. 
Preostali dio stanica je nabubrio sa 0.075 M KCI, ispran sa tri uzastopne promjene fiksativa (metanol:glacijalna octena kiselina, 3:1 vol./vol.
The antibody of any of the preceding claims wherein said polypeptide chain is a light chain of a type selected from λ and k. 
Antitijelo iz bilo kojeg od prethodnih patentnih zahtjeva gdje spomenuti polipeptidni lanac je laki lanac tipa odabranog od Xi K.
The method for the preparation of the agomelatine hydrochloride hydrate according to claim 3, wherein agomelatine is added to an aqueous organic solvent containing HCl to precipitate the crystal of the product. 
Postupak za pripremu agomelatina hidroklorid hidrata u skladu s patentnim zahtjevom 3, naznačen time, da se agomelatin dodaje vodenom organskom otapalu koje sadrži HCI da se istaloži kristal proizvoda.
In another specific embodiment, the present invention provides a liquid formulation comprising: 0.001-50 mg/ml of mature elastase protein in a solution of 137 mM sodium chloride, 2.7 mM potassium phosphate, 10 mM sodium phosphate and comprising 0.01% polysorbate-80, with a pH of 7.4. In another specific embodiment, the present invention provides a liquid formulation comprising: 0.001-50 mg/ml of mature elastase protein in a solution of 137 mM sodium chloride, 2.7 mM potassium phosphate, 10 mM sodium phosphate and comprising 0.01 % polysorbate-80 and 8% dextran-18, with a pH of 7.4. 
(ii) koncentracija zrelog tipa I protein elastaze u spomenutom farmaceutskom sastavu je 0.001 - 50 mg/ml i farmaceutski sastav sadrži 5-10% ili 6-9% ekscipijensa izabranog iz dekstroze, laktoze, manitola, saharoze, trehaloze, dekstrana-70, glicerina, arginina, glicina, dekstrana-44 ili dekstrana-18; ili (iii) koncentracija zrelog tipa I protein elastaze u spomenutom farmaceutskom sastavu je 0.001-50 mg/ml i sastav dalje sadrži 8% dekstrana-18 i opcionalno 0,1% polisorbat-80; ili
“C1-6alkyl” means a straight chain or branched, noncyclic or cyclic, unsaturated or saturated aliphatic hydrocarbon containing from 1 to 6 carbon atoms. 
"Cygalkil" znači ncrazgranati ili razgranati, neciklički ili ciklički, nezasićeni ili zasićeni alifatski ugljikovodik s 1 do 6 atoma ugljika.
Process according to claim 19 or 20 wherein said coupling reaction is followed by further modifying Ar1, Y1, X, Ar2, Y2, R', Z, R", R'" of the compound of formula (I) obtained so as to obtain the desired compound of formula (I). 
Postupak prema patentnom zahtjevu 15 ili 16, gdje za navedenom reakcijom kondenzacije slijedi daljnja modifikacija Arl, Y1, X, Ar2, Y2, R', Z, R", R'" u tako dobivenom spoju formule (1), kako bi se dobilo željeni spoj formulc (1).
The preparation method according to any of claims 3-6, wherein when the temperature of the resulting reaction mixture reaches 19-25°C, and especially when around 22°C or 23°C, water is added dropwise in order to bring about crystallization. 
Postupak pripreme u skladu s bilo kojim od patentnih zahtjeva 2 do 5, naznačen time, da kada temperatura dobivene reakcijske smjese dosegne 19 do 25 °C, a posebno kada dosegne oko 22 °C ili 23 °C, dodaje se voda kap po kap kako bi se postigla kristalizacija.
A process for the crystallisation of a water-soluble compound from a solution comprising the following steps: 
Postupak kristalizacije spoja topivog u vodi iz otopine koji sadrži sljedeće korake:
Solvent is evaporated off and to obtain a yellow solid residue. 
Otapalo je upareno u dobivena je žuta krutina. Iskorištenje:
The composition of Claim 5, which further comprises an agent selected from B2 adrenergic receptor agonists, steroidal anti-inflammatory agents, phosphodiesterase-4 inhibitors, and combinations thereof; wherein the crystalline form and the agent are formulated together or separately. 
Pripravak u skladu s patentnim zahtjevom 5, naznačen time, da nadalje sadržava agense odabrane od agonista B2 adrenergičkih receptora, steroidnih protuupalnih agensa, inhibitora fosfodiesteraze-4 i njihovih kombinacija; pri čemu su kristalni oblik i agens formulirani zajedno ili odvojeno.
a targeter-RNA comprising a nucleotide sequence that is complementary to, and hybridizes with, a target sequence of a target DNA inside of one or more target cells of said population of target cells; and 
segment koji cilja na DNK, te koji obuhvaća nukleotidnu sekvencu koja je komplementarna ciljanoj sekvenci u ciljanoj DNK; i
The preferred salts are maleates. 
Prvenstvene soli su maleati.
A vaporizer 45, a gas-liquid separator 46, and a heater 47 are installed in the sub LNG supply line L 24 so as to adjust the methane number and temperature of LNG supplied as fuel to the value required in the DF engine. 
Postupak obrade ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se, kada se LNG uskladišten u spremniku za teret dovodi u pomoćni motor, teške ugljikovodike kao komponentu odvaja od LNG-a kako bi se podesilo metanski broj L.NG-a do vrijednosti potrebne za pomoćni motor.
The apparatus according to claim 1, wherein the lower threshold value of the current that is delivered and absorbed is a minimum value (IMIN) of current delivered by the plant-controller electronic card, such as to guarantee a minimum current on an axle of the train that is sufficient for detection of the codes on board the train under worst conditions. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što je iznos nižeg praga apsorbirane struje minimalni iznos (IMIN) struje isporučene od elektroničke kartice za upravljanje uređajem, tako da se garantira minimalna struja na osovini vlaka koja je dovoljna za detektiranje kodova na komandnoj ploči vlaka u najgorim uvjetima, naime za maksimalnu duljinu i za maksimalno rasipanje.
The integrated circuit according to claim 13, wherein, the reception circuitry, in operation, controls reception of higher layer control information indicating control of the transmission power value of the A-SRS using the second accumulation value. 
Postupak radio komunikacije sukladno zahtjevu 5, sadržeći primanje kontrolne informacije višeg sloja, naznačeno time da se navedeno upravljanje vrijednosti snage prijenosa A-SRS-a inicira nakon navedenog primanja kontrolne informacije višeg sloja.
FIG. 2 is a side view of a sub-assembly of the machine shown in FIG. 
Slika 2 je bokocrt podsklopa stroja prikazan na Slici 1, gdje navedeni podsklop sadrži jedinicu za kuhanje;
providing a first web (171) having a series of parallel grooves with a three-sided polygonal cross section; 
(i) osiguravanje prve mreže (171) s nizom paralelnih žljebova s poligonalnim trostranim poprečnim presjekom;
The crude product was purified by flash chromatography on silica using gradient elution (heptane/ethyl acetate). 
Sirovi produkt se pročišćava brzom kromatografijom na silika gelu uz korištenje gradijenta ispiranja (heptan/etil acetat).
After cooling, the insoluble material was collected and stirred in methanol (10 ml). 
Nakon hlađenja, neotopljeni materijal se sakupi i miješa u metanolu (10 ml).
The method according to claim 9, further comprising the procedure of determining priorities for responding to multiple incoming threats, by assigning to each of said threats a priority based on parameters of the received radiation associated with the threat. 
Metoda u skladu sa zahtjevom 7, naznačena time da nadalje obuhvaća postupak određivanja prioriteta za reagiranje na više dolaznih prijetnji, dodjeljivanjem svakoj od navedenih prijetnji prioritet na temelju parametara primljenog zračenja povezanog s prijetnjom.
receiving notification (200) at the central server relating to a change in the current location for the subscribed device; determining (202) from the notification and from a list of subscriber network identifiers allocated to the subscribed device whether a new subscriber network identifier is to be provisioned from the central server; selecting a subscriber network identifier on the basis of the current location, if the determining step has determined that a new subscriber network identifier is to be provisioned; and 
detektiranju poruke o obnavljanju lokacije u središnjem čvoru, gdje poruka o obnavljanju lokacije odgovara promjeni trenutne lokacije pretplatničkog mobilnog komunikacijskog uređaja (10, 20, 101); određivanju iz trenutne lokacije za pretplatnički mobilni komunikacijski uređaj (10, 20, 101) i identifikatora pretplatničkih mreža koji su trenutno aktivni ili spremljeni u pretplatničkom mobilnom komunikacijskom uređaju (10, 20, 101) treba li novi identifikator pretplatničke mreže poslati na pretplatnički mobilni komunikacijski uređaj (10, 20, 101);
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) fluopyram. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) fludioksonil.
The method of claim 2, wherein the modified oligonucleotide has a nucleobase sequence that is at least 95% complementary to a human TMPRSS6 nucleic acid. 
(i) ima nukleobaznu sekvencu koja je bar 95%, bar 99%, ili 100% komplementarna sa nukleinskom kiselinom za TMPRSS6; i/ili
wherein the apparatus is configured to use, in context-adaptive entropy encoding each of the syntax elements, a context which is selected for each of the syntax elements based at least on a size of the transform coefficient block, a position of the syntax element within the transform coefficient block, and information regarding prior syntax elements previously encoded in a neighborhood of the position of the syntax element, wherein contexts for different syntax elements are selected based on different combinations of the size of the transform coefficient block, the position of the respective syntax element and the information regarding the respective prior syntax element previously encoded. 
Uređaj prema zahtjevu 4 ili 5, naznačen time, da je dokoder (250) nadalje konfiguriran tako, da između elemenata sintakse prvog tipa koji pokazuju da je na odgovarajućoj pridruženoj poziciji smješten signifikantni koeficijent transformacije i elemenata sintakse prvog tipa koji neposredno slijede, izvlači elemente sintakse drugog tipa iz protoka bitova, koji za pridružene pozicije na kojima su smješteni signifikantni koeficijenti transformacije, pokazuju da li je odgovarajuća pridružena pozicija posljednji signifikantni koeficijent transformacije u bloku koeficijenata transformacije.
R10a and R10b taken together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl; and is —NR1aR2a, 
R'*%i R'" uzeti zajedno s atomom ugljika za koji su pričvršćeni tvore 3- do 6- člani cikloalkil; i
The composite of any one of claims 1 to 4, wherein the cationic cellulose has a degree of substitution of the cationic substituent selected in a range from 0.5 to 3 weight percent. 
Ploča na bazi gipsa prema zahtjevu 1, naznačena time, da kationski škrob ima mjeru supstitucije odabranu u rasponu od 0,5 do 3 masenih %.
The method of claim 1, wherein step 1c) comprises the further step of creating a k x m-Beta random number matrix (Beta), wherein said m elements of the first data-set are represented by an m-element column vector (VA) and said k encoded elements are represented by a k-element column vector (VY), which is computed by performing the matrix multiplication of the Beta random number matrix and the m-element column vector; wherein prior to performing step 1f) each of the k encoded elements is encapsulated along with the entries of the respective row of the Beta random number matrix into a separate packet to be transmitted; and wherein step 1g) comprises the step of computing the inverse of said received Beta random number matrix, wherein the m-element column vector is computed by performing the matrix multiplication of the inverse of said Beta random number matrix and the k-element column vector. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što korak 1c) uključuje dodatni korak generiranja k × m-Beta matrice slučajnih brojeva (Beta), gdje navedenih m elemenata prvog podatkovnog niza predstavlja vektor stupca m-elemenata (VA), a navedenih k kodiranih elemenata predstavlja vektor stupca k elemenata (VY), što se izračunava matričnim množenjem Beta matrice slučajnih brojeva s vektorom stupca m-elemenata; gdje se prije provedbe koraka 1f) svaki od k kodiranih elemenata učahuruje uz članove odgovarajućeg reda Beta matrice slučajnih brojeva u odvojeni paket kojeg treba predati; te gdje korak 1g) uključuje korak izračunavanja inverzije navedene primljene Beta matrice slučajnih brojeva, gdje se vektor stupca m-elemenata izračunava matričnim množenjem inverzije navedene Beta matrice slučajnih brojeva s vektorom stupca k elemenata.
a telescopic driving shaft (9); 
- teleskopska pogonska ručka (9);
The DMF and interferon-beta for use according to claim 12, wherein the interferon-beta 1 a is to be administered at a dose of 5 mcg to 80 mcg at one time. 
Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 9, naznačena time što interferon-B1a treba primijeniti u dozi od 5 µg do 80 µg odjednom.
amino acid residues at framework positions 1, and 87 of the variable light chain according to the Kabat numbering scheme are substituted, wherein the substituted amino acid at framework position 1 is serine (S), and the substituted amino acid at framework position 87 is phenylalanine (F); and 
(i) aminokiselinski ostatci na okvirnim pozicijama 1, 67 i 87 od varijabilnog slabog lanca prema shemi numeriranja Kabat, supstituirani s ne-humanim ostatcima, dok ne-humani ostatak na okvirnoj poziciji 1 je serin (S), ne-humani ostatak na okvirnoj poziciji 67 je tirozin (Y) i ne-humani ostatak na okvirnoj poziciji 87 je fenilalanin (F); i